POT-4 (TFA)

CN1C2=CC=CC=C2C(C[C@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)C)=O)NC([C@@H](NC(C)=O)[C@@H](C)CC)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)=O)CCCNC(N)=N)=O)CC4=CN=CN4)=O)C)=O)=O)CC5=CNC6=CC=CC=C56)=O)CC(O)=O)=O)CCC(N)=O)=O)=C1.O=C(O)C(F)(F)F

[1]S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.|[2]Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40 (1) :18-26.